171 related articles for article (PubMed ID: 21035354)
41. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.
Hatfield KJ; Olsnes AM; Gjertsen BT; Bruserud Ø
Curr Cancer Drug Targets; 2005 Jun; 5(4):229-48. PubMed ID: 15975045
[TBL] [Abstract][Full Text] [Related]
42. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P; Novák J; Novák M
Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
[TBL] [Abstract][Full Text] [Related]
43. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Choi HJ; Armaiz Pena GN; Pradeep S; Cho MS; Coleman RL; Sood AK
Cancer Metastasis Rev; 2015 Mar; 34(1):19-40. PubMed ID: 25544368
[TBL] [Abstract][Full Text] [Related]
44. Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.
Smith MA
Pediatr Blood Cancer; 2014 Aug; 61(8):1497-505. PubMed ID: 24760743
[TBL] [Abstract][Full Text] [Related]
45. Exosomes derived from acute myeloid leukemia cells promote chemoresistance by enhancing glycolysis-mediated vascular remodeling.
Wang B; Wang X; Hou D; Huang Q; Zhan W; Chen C; Liu J; You R; Xie J; Chen P; Huang H
J Cell Physiol; 2019 Jul; 234(7):10602-10614. PubMed ID: 30417360
[TBL] [Abstract][Full Text] [Related]
46. [Tryptase relation to VEGF in acute leukemia].
Li Y; Zhang R; Lu XL; Wang PP; Fan H; Lü XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):793-7. PubMed ID: 16277844
[TBL] [Abstract][Full Text] [Related]
47. Inhibitors of Angiogenesis in Cancer Therapy - Synthesis and Biological Activity.
Gensicka M; Głowacka A; Dzierzbicka K; Cholewinski G
Curr Med Chem; 2015; 22(33):3830-47. PubMed ID: 26337104
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.
Fallah A; Sadeghinia A; Kahroba H; Samadi A; Heidari HR; Bradaran B; Zeinali S; Molavi O
Biomed Pharmacother; 2019 Feb; 110():775-785. PubMed ID: 30554116
[TBL] [Abstract][Full Text] [Related]
49. Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better.
Usui-Ouchi A; Friedlander M
J Clin Invest; 2019 Jun; 129(8):3032-3034. PubMed ID: 31232702
[No Abstract] [Full Text] [Related]
50. Antiangiogenic therapies in non-Hodgkin's lymphoma.
Ruan J
Curr Cancer Drug Targets; 2011 Nov; 11(9):1030-43. PubMed ID: 21933106
[TBL] [Abstract][Full Text] [Related]
51. Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors.
Kang Y; Li H; Liu Y; Li Z
J Cancer Res Clin Oncol; 2024 Apr; 150(5):221. PubMed ID: 38687357
[TBL] [Abstract][Full Text] [Related]
52. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
Reardon DA; Wen PY; Desjardins A; Batchelor TT; Vredenburgh JJ
Expert Opin Biol Ther; 2008 Apr; 8(4):541-53. PubMed ID: 18352856
[TBL] [Abstract][Full Text] [Related]
53. Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects.
van der Giet M; Henkel C; Schuchardt M; Tolle M
Curr Pharm Des; 2015; 21(24):3548-56. PubMed ID: 25714990
[TBL] [Abstract][Full Text] [Related]
54. Angiogenesis: a target in solid tumors, also in leukemia?
Schmidt T; Carmeliet P
Hematology Am Soc Hematol Educ Program; 2011; 2011():1-8. PubMed ID: 22160005
[TBL] [Abstract][Full Text] [Related]
55. Acute myeloid leukemia in the vascular niche.
Cogle CR; Bosse RC; Brewer T; Migdady Y; Shirzad R; Kampen KR; Saki N
Cancer Lett; 2016 Oct; 380(2):552-560. PubMed ID: 25963886
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies.
Podar K; Anderson KC
Cell Cycle; 2007 Mar; 6(5):538-42. PubMed ID: 17351339
[TBL] [Abstract][Full Text] [Related]
57. Curcumin and turmeric attenuate arsenic-induced angiogenesis in ovo.
Pantazis P; Varman A; Simpson-Durand C; Thorpe J; Ramalingam S; Subramaniam D; Houchen C; Ihnat M; Anant S; Ramanujam RP
Altern Ther Health Med; 2010; 16(2):12-4. PubMed ID: 20232614
[TBL] [Abstract][Full Text] [Related]
58. Adaptation to antiangiogenic therapy in neurological tumors.
Flanigan PM; Aghi MK
Cell Mol Life Sci; 2015 Aug; 72(16):3069-82. PubMed ID: 25943307
[TBL] [Abstract][Full Text] [Related]
59. Vascular endothelial growth factor pathway.
Krupitskaya Y; Wakelee H
J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1071-3. PubMed ID: 19861922
[No Abstract] [Full Text] [Related]
60. Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors.
Khodabakhsh F; Muyldermans S; Behdani M; Kazemi-Lomedasht F
J Drug Target; 2020 Apr; 28(4):379-385. PubMed ID: 31822133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
